Like pharma giants Pfizer, Eli Lilly and Merck & Co, US biotechnology major Biogen Idec also doesn’t want to miss the India opportunity.

Avesthagen’s systems biology approach to novel products targets more than land based organisms - dives deep into new products from the Ocean

Avesthagen has always been in the forefront of innovative scientific thinking and has developed a formidable portfolio of patents in all the four areas it operates in viz. bioAgriculture, bioNutrition, bioPharmacueticals and in Science & Innovation.  Approximately 600 patent applications cover both, process and products. There are several copyrights and design patents as well.  Within each area Avesthagen aspires to benefit the common man, and more so for the “bottom of the pyramid”.

Indian drugmakers could see excise duty on drugs restored to 8 percent from the present 4 percent, but they are hopeful research & development could attract some tax sops in the Union budget on Feb. 26.

After witnessing a neutral budget last year, the Indian pharmaceutical industry has prepared itself again with its wish list for Budget 2010.